SPIDER Surgery
About TransEnterix

The Latest News

Bariatric-News100Surgeon performs sleeve using flex ligating article

NYSXTransEnterix, Inc. Rings Opening Bell at the New York Stock Exchange. watch video

WomansOrgLouisiana bariatric surgeon first in world to use SPIDER flexible ligating sheers. read article

TriangleBusinessJournalTransEnterix focuses on market for surgical robots. read article

Advancing Laparoscopic Surgery Through Innovation

As a company we engineer and launch products that help reduce the invasiveness of surgery for patients while enhancing the capabilities of surgeons.

At TransEnterix, innovation is a collaborative process where practicing surgeons partner with engineers to design, prototype and test new advances in surgery.


In development, and not yet cleared by the FDA or available on the market, the SurgiBot™ System is designed as a reduced incision, patient-side robotic surgery system. The system is intended to bring many of the advantages of robotic assistance to laparoscopic surgery while mitigating many of the drawbacks of existing robotic surgery systems.


The SPIDER flexible laparoscopic platform allows multiple instruments to be used through one incision. The goal of SPIDER surgery is to facilitate fewer incisions and a fast recovery for the patient. The SPIDER device is no longer available to new customers in the U.S. as TransEnterix focuses on the development and commercialization of the SurgiBot.


From its start, TransEnterix set out to become a different kind of medical device company.

Partnering closely with world-renowned surgeons, TransEnterix relies on rapid prototyping, intense pre-clinical labs and hands-on collaboration to accelerate learning and bring new technologies to market more quickly.

*The SurgiBot has not been cleared by the FDA for use in the United States